Last reviewed · How we verify
NCT05246059: COVANOS
Anosmia and Covid-19
NA trial testing Olfactory Training in Anosmia in 63 participants. Completed in 8 August 2021.
8 August 2021
Quick facts
| Lead sponsor | University College, London |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 63 |
| Start date | 3 June 2020 |
| Primary completion | 8 August 2021 |
| Estimated completion | 8 August 2021 |
| Sites | 4 locations across United Kingdom |
Drugs / interventions tested
- Olfactory Training
Conditions studied
- Anosmia — all drugs for Anosmia →
- SARS CoV 2 Infection — all drugs for SARS CoV 2 Infection →
Sponsor
University College, London
Who can join
18 and older, any sex, with Anosmia or SARS CoV 2 Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our study aims to determine the prevalence of anosmia in patients SARS-Cov-2/Covid-19 infection (both by symptom reporting and smell testing), the efficacy of early olfactory training for the treatment of anosmia caused by infection and the long-term impact of smell dysfunction with a one-year follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05246059
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Olfactory Training
Trials testing the same drug.
- NCT06327633 — Effects of Olfactory Training on the Brain Function in T2DM Patients With Mild Cognitive Impairment · NA · completed
- NCT05448898 — The Efficacy of Traditional Chinese Medicine in Olfactory Dysfunction · NA · unknown
- NCT05364125 — Olfactory Training on Smell Dysfunction Patients in HK · NA · recruiting
- NCT04952389 — Acupuncture Therapy for COVID-Related Olfactory Loss · NA · completed
Other recruiting trials for Anosmia
Currently open trials in the same condition.
- NCT06733636 — Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults · NA · recruiting
- NCT05562050 — Characteristics of the Anosmic Olfactory Mucosa · active not recruiting
- NCT05040659 — Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2 · active not recruiting
- NCT05364125 — Olfactory Training on Smell Dysfunction Patients in HK · NA · recruiting
- NCT06423495 — Efficacy of Photobiomodulation in the Rehabilitation of Olfactory Dysfunctions Induced by Long COVID-19 · NA · recruiting
Other University College, London trials
Trials by the same sponsor.
- NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
- NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
- NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
- NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
- NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05246059 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University College, London
- Last refreshed: 18 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05246059.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing